Practice Areas -

Equity Capital Markets Law Firms and Lawyers

  • Search Result as
  • By Days
  • Between Dates

Practice Areas - Equity Capital Markets Law Firms and Lawyers

Deal Date: 09-07-2020 Practice Area: Equity Capital Markets
Deal Title: Ocumension Therapeutics HKSE Initial Public Offering Industry: Pharmaceuticals & Biotechnology
Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HKD1.55 billion (USD200.4 million) prior to any exercise of the over-allotment option. Ocumension is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies and has, in less than three years, built a strategically designed ophthalmic drug portfolio that is comprehensive, innovative and validated.
Financial Center: Hong Kong Value: 100.01-500.00
Advised Party: Underwriter Law Firm
Issuer Jurisdiction- China Listing Jurisdiction- Hong Kong
Classification: Initial Public Offerings Hong Kong Stock Exchange
Lawyer Li He